SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-02

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Renal cancer ranks seventh in incidence among men and sixth among women in the Beijing area, with Peking University First Hospital treating over 1,000 kidney cancer patients annually. Once recurrence or metastasis occurs, the prognosis is poor, with median progression times of 1-2 years after first-line systemic therapy (targeted therapy combined with immunotherapy). Enhancing local control of lesions is key to improving overall survival. Combining local radiotherapy with systemic treatment may be one approach to address this issue. Currently, Stereotactic Ablative Radiotherapy (SABR) enables precise tumor ablation and can activate the body's immune response. Studies show that the one-year local control rate after SABR exceeds 90%. Preliminary research by the applicant has shown that the combination of drug therapy and SABR for recurrent metastatic renal cancer can extend progression-free survival beyond two years, with earlier intervention leading to more significant survival improvements. This study aims to evaluate the efficacy and safety of combining SABR with targeted and immunotherapy for recurrent metastatic renal cancer through a multicenter, bidirectional cohort design, exploring new therapeutic strategies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

NCT06889649

Radiation Therapy Targeted Therapy Immunotherapy +1 more

RECRUITING PHASE2

Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer

NCT05567588

Clear-cell Metastatic Renal Cell Carcinoma

RECRUITING PHASE2

A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma

NCT03736330

Renal Cancer Metastatic

UNKNOWN PHASE2

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

NCT06323239

Nasopharyngeal Carcinoma

RECRUITING PHASE2

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

NCT03987698

Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Radiation Therapy Metastatic Renal Cancer Recurrent Renal Cell Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RT group

In conjunction with targeted and immunotherapy, administer radiation therapy to achieve as complete coverage as possible of all identifiable primary and metastatic lesions.

Radiation therapy

Intervention Type RADIATION

Administer radiation therapy to achieve as complete coverage as possible of all identifiable primary and metastatic lesions in conjunction with targeted and immunotherapy

Targeted and immunotherapy

Intervention Type DRUG

Targeted and immunotherapy

Control group

Targeted and immunotherapy

Intervention Type DRUG

Targeted and immunotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiation therapy

Administer radiation therapy to achieve as complete coverage as possible of all identifiable primary and metastatic lesions in conjunction with targeted and immunotherapy

Intervention Type RADIATION

Targeted and immunotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with histologically confirmed renal cancer; diagnosed with recurrent or metastatic renal cancer via PET/CT or other whole-body imaging.
* Evaluated by the radiation oncology and imaging departments as having at least one lesion amenable to radiation therapy.
* Planning to undergo or currently receiving first-line or second-line targeted therapy combined with immunotherapy.
* Voluntarily agrees to participate in the study and signs an informed consent form.
* Male or female, aged ≥18 years (inclusive).
* Expected survival of ≥12 weeks.
* At least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
* European Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate cardiac, bone marrow, liver, and renal function.
* Willing and able to comply with the study procedures and follow-up schedule.

Exclusion Criteria

* Extensive, multiple metastases;
* Presence of central nervous system metastases and/or carcinomatous meningitis.
* Toxicity from previous treatments not yet recovered to grade 0-1 (excluding grade 2 alopecia);
* Other severe, uncontrollable co-morbid conditions that could affect protocol compliance or confound interpretation of results, including active opportunistic or severe progressive infections, uncontrolled diabetes, uncontrolled hypertension, cardiovascular diseases (defined as New York Heart Association Class III or IV heart failure, second-degree or higher heart block, myocardial infarction within the last 12 months, unstable arrhythmias or angina, stroke within the last 6 months), or pulmonary diseases (interstitial pneumonia, obstructive pulmonary disease, and symptomatic bronchospasm history), deep vein thrombosis or pulmonary embolism within the last 6 months;
* Diagnosed with other malignancies within 5 years prior to enrollment, except:
* Localized low-risk prostate cancer (defined as stage ≤T2b, Gleason score ≤7, and PSA ≤20ng/mL at diagnosis, who have undergone curative treatment with no recurrence of prostate-specific antigen);
* Malignancies treated with a curative intent that are considered cured, including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with surgery;
* Pregnant or breastfeeding women;
* Positive HIV test result;
* Active hepatitis B or C infection;
* Active tuberculosis;
* Any other conditions, metabolic abnormalities, physical examination or laboratory findings that in the investigator's judgment might indicate an unsuitability for the study drug, could interfere with the interpretation of study results, or place the patient at high risk if they participate in the study;
* Estimated insufficient compliance with the clinical study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No